Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v2-FR Version v1-EN
Language French English
Date Updated 2024-12-10 2024-12-10
Drug Identification Number 02253631 02253631
Brand name TEVETEN PLUS TEVETEN PLUS
Common or Proper name EPROSARTAN EPROSARTAN
Company Name BGP PHARMA ULC BGP PHARMA ULC
Ingredients HYDROCHLOROTHIAZIDE EPROSARTAN HYDROCHLOROTHIAZIDE EPROSARTAN
Strength(s) 12.5MG 600MG 12.5MG 600MG
Dosage form(s) TABLET TABLET
Route of administration ORAL ORAL ORAL ORAL
Packaging size 2x14 2x14
ATC code C09DA C09DA
ATC description ANGIOTENSIN II ANTAGONISTS, COMBINATIONS ANGIOTENSIN II ANTAGONISTS, COMBINATIONS
Reason for discontinuation Business reasons Business reasons
Anticipated discontinuation date
Actual discontinuation date 2023-08-30 2023-08-30
Remaining supply date 2022-08-31 2022-08-31
Discontinuation status Discontinued Discontinued
Discontinuation decision reversal no no
Tier 3 Status No No
Information on remaining supply
Company comments
Health Canada comments